Non-viral circular ssDNA delivery associated to TALEN® gene editing allows high levels of gene insertion in long-term repopulating HSPCs NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the ...
On September 26, 2025, Factor Bioscience Inc. (“Factor”) filed a complaint against Cellectis Inc., Cellectis SA, AstraZeneca PLC, AstraZeneca Ireland Limited, and AstraZeneca Holdings B.V., alleging ...
Cancer drug developer Allogene Therapeutics (NASDAQ:ALLO) announced on Tuesday that its licensor, Cellectis (NASDAQ:CLLS), is facing a lawsuit in the U.S. over allegations of patent infringement ...
CELLS develops off-the-shelf TALEN-edited CAR-T therapies. Its main in-house asset is lasme-cel for r/r B-ALL and eti-cel for r/r B-cell NHL. Early data show that lasme-cel reached impressive ORRs in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results